• Advanced Mineral Active Ingredients: Patented dispersions of zinc oxide and titanium dioxide engineered to provide high-performance, photostable, and aesthetically pleasing mineral-based sun protection for skincare and cosmetic products.
• Color Adapting & Correction Technologies: Proprietary ingredient systems that offer adaptive tinting and color-correcting properties for cosmetic formulations, particularly to reduce the white cast often associated with mineral sunscreens.

Solesence (SLSN) primarily operates as an ingredient brand, selling its patented mineral-based active ingredients and advanced formulations to other companies in the beauty and personal care industry. Therefore, its major customers are other businesses rather than individuals.

According to Solesence's official press release issued on December 1, 2023, regarding its Nasdaq listing, the company is recognized as a "science-backed mineral ingredient supplier and trusted development partner for numerous leading global beauty and personal care brands." The release specifically named the following brands and their parent companies as examples of entities utilizing Solesence's technology:

• LVMH Moët Hennessy Louis Vuitton SE (parent company of Sephora) - Symbol: LVMUY (OTCPK)
• The Estée Lauder Companies Inc. (parent company of Clinique and other Estée Lauder brands) - Symbol: EL (NYSE)
• Shiseido Company, Limited - Symbol: SSDOY (OTCPK)
• Supergoop! (Private Company)
• Tula Skincare (Private Company)

It is important to note that while these brands are publicly mentioned by Solesence as partners or users of their ingredients, the company's SEC filings indicate that revenue is concentrated among a limited number of customers, none of whom individually accounted for more than 20% of total revenue in recent periods, and the specific names of their top revenue-generating customers are not typically disclosed.

Kevin Cureton, President and Chief Executive Officer

Kevin Cureton joined Solesence in November 2012, and on September 3, 2025, was appointed President and Chief Executive Officer. He previously served as Chief Operating Officer since December 2019 and Chief Commercial Officer since January 2018. With over twenty years of experience in the chemical industry, primarily in personal care, Kevin founded and served as Managing Director of the skin care and dermatology technology business at AMCOL International Corporation for twelve years. He also held significant roles at Air Products and Borden.

Laura Riffner, Chief Financial Officer

Laura Riffner was appointed Chief Financial Officer on September 3, 2025, bringing more than 35 years of financial and operational expertise to Solesence. From 2002 to 2024, she served as Chief Financial Officer and later Chief Finance and Strategy Officer at Nagase America, a global distributor and manufacturer of specialty chemicals. In this role, she streamlined budget planning and analysis, enhanced operations management, and successfully oversaw the company's acquisition of Fitz Chem. Laura also served as Chief Financial Officer at Paxton/Patterson, an education technology firm.

Dr. Harry Sarkas, Chief Scientific Officer

Dr. Harry Sarkas oversees technology platform innovation at Solesence. He is an expert in photophysics and related chemistries with over 25 years of direct experience in material synthesis, production, characterization, and product development. Dr. Sarkas is the author or co-author of over 45 patents, including Active Stress Defense™ and Kleair™ technologies, and has authored over 40 technical publications.

Yoana Dvorzsak, Vice President of Innovation and Product Integrity

Yoana Dvorzsak supervises all external client programs, guiding development from concept to launch. With a strong formulation background, she has developed skin care and color cosmetics products for multiple global brands and is experienced in regulatory compliance. She was promoted to Vice President of Innovation and Product Integrity in November 2025.

Harrison King, VP, Operations

Harrison King oversees all manufacturing and supply chain operations for Solesence, including bulk production, filling, and purchasing. He brings over 25 years of experience in manufacturing, problem-solving, scheduling, preventative maintenance, project management, quality systems, and P&L management. Harrison is well-versed in lean concepts and the theory of constraints, and his previous experience includes management roles at companies such as Blistex and Avon.

Solesence (SLSN) is expected to drive future revenue growth over the next two to three years through a combination of strategic initiatives focused on innovation, market expansion, and operational enhancements:

1. Expansion of Brand Partnerships and Product Portfolio: Solesence anticipates growth by securing new brand partners and deepening relationships with existing ones, driven by large customer orders and the introduction of new product lines. The company launched over two dozen new SKUs and secured two new patents in Q4 2024, emphasizing its commitment to innovation and expanding its offerings in skincare, sun care, and color cosmetics.
2. Strategic Transformation and Operational Efficiency: The company is undergoing a strategic transformation, including executive promotions and the consolidation of manufacturing facilities from three to two, alongside increased automation. These efforts are aimed at enhancing innovation, product quality, and overall operational efficiency, which are expected to lead to more cost-effective production and delivery of high-quality products to brand partners.
3. Leveraging Proprietary Technology and Scientific Innovation: Solesence positions itself as a leader in scientifically-driven healthcare solutions, utilizing its proprietary technology to develop unique, high-performance products. The company holds global patent protection for key technologies, including Kleair™ technology, a plant-based antioxidant technology, and a skin health and healing technology. This intellectual property expansion underpins its ability to offer differentiated products and maintain a competitive edge.

Share Issuance

• Solésence's additional paid-in capital increased by approximately $649,000 between the fourth quarter of 2024 ($114,674,000) and the third quarter of 2025 ($115,323,000), indicating share issuance activity.
• In 2024, the company received an equity injection, provided by one of its line of credit providers, to support its capital needs.
• Common shares outstanding were 70,103,279 as of March 31, 2025.

Inbound Investments

• On October 31, 2025, Solésence, Inc. entered into a settlement agreement with Solarium Brands, LLC and A-Frame Brands, LLC, which includes a one-time settlement payment of $675,000 to Solésence on or before January 15, 2026. This payment resolves disputes related to previously sold consumer care products.

Capital Expenditures

• In 2025, Solésence consolidated its manufacturing operations from three facilities to two and increased automation to enhance efficiency and product quality.
• The company continues to have high capital needs to sustain its rapid growth, which includes investments in property, plant, and equipment (PP&E).
• In May 2025, Solésence expanded its existing debt facilities, increasing borrowing capacity from $14.2 million to $23.0 million, with the additional capacity intended to support strategic objectives such as the procurement of raw materials and improved lead times for product launches.